In an analysis of 1058 patients’ pathological reports with advanced melanoma treated with anti-PD-1 or anti-PD-L1 antibodies, Eroglu et al. identified 60 patients with advanced desmoplastic melanomas, who overall had a high response rate to PD-1 blockade. This evidence concerns the gene CD274 and melanoma.